Ionis Pharmaceuticals, Inc. (IONS) Discusses FDA Approval and Launch Strategy for ZANVASTRO in Alexander Disease Transcript

Ionis Pharmaceuticals, Inc. ( IONS ) Discusses FDA Approval and Launch Strategy for ZANVASTRO in Alexander Disease September 4, 2026 10:00 AM EDT Company Participants D. Walke - Senior Vice President of Investor Relations Brett Monia - Founder, CEO & Director Holly Kordasiewicz - Executive VP & Chief Development Officer Kyle Jenne - Executive VP & Chief Global Product Strategy Officer Conference Call Participants Steven Ionov - TD Cowen, Research Division Denis Reznik - Canaccord Genuity Corp., Research Division Salveen Richter - Goldman Sachs Group, Inc., Research Division Chi Meng Fong - BofA Securities, Research Division Avraham Novick - Morgan Stanley, Research Division Silvia Luo - JPMorgan Chase & Co, Research Division Eric Joseph - Citigroup Inc., Research Division David Lebowitz Yale Jen - Laidlaw & Company ( UK ) Ltd., Research Division Myles Minter - William Blair & Company L.L.C., Research Division Moritz Reiterer - Guggenheim Securities, LLC, Research Division

Good morning, and welcome to Ionis conference call to discuss the FDA approval of ZANVASTRO for treatment of Alexander disease. As a reminder, this call is being recorded. At this time, I would like to turn the call over to Wade Walke, Senior Vice President of Investor Relations, to lead the call. Please begin.

Thank you, Joel, and thank you to everyone joining us today as we discuss ZANVASTRO, which is now the first and only FDA-approved disease-modifying therapy for the treatment of Alexander's disease. Please be sure to visit the Investors section of the Ionis website to see the press release Ionis has issued earlier today, along with the slides accompanying today's webcast. Before we begin, I would like to remind you that our discussion today will contain forward-looking statements that are based on our current expectations and beliefs. Such statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage